scholarly journals The importance of immunosupression in the development of the heavy form of cytomegaloviral infection in newborn children

2021 ◽  
Vol 12 (4) ◽  
pp. 108-115
Author(s):  
L. V. Kravchenko
Keyword(s):  
Monoclonal Antibodies ◽  
B Cell ◽  
Research Methods ◽  
Cytomegalovirus Infection ◽  
Severe Form ◽  
Membrane Markers ◽  
Cell Immunity ◽  
Systems Of Inequalities ◽  
Heavy Form ◽  
Newborn Children

Objective: to study the features of disorders in T and B cell immunity and the synthesis of serum immunoglobulins of classes IgA, IgM, IgG with the aim of predicting severe cytomegalovirus infection (CMVI) in newborns.Research methods: 133 newborns with cytomegalovirus infection were examined. Lymphocytes were typed to differentiation clusters CD3, CD4, CD8, CD20 using monoclonal antibodies, IMMUNOTECH (France). The expression of membrane markers of immunocompetent cells was determined using a Beckman COULTER EpicsXLII flow laser cytofluorimeter. Depending on the severity of the condition, all children were divided into two groups: 1 — CMVI, severe form — 60 people (45,1%); 2 CMVI, moderate form — 73 people (54,9%).Results. Using the «classification trees» method, we were able to develop a differentiated approach to the prognosis of a severe form of CMVI in newborn children. Systems of inequalities were obtained, four of which classify a subgroup of newborns with severe CMVI. Conclusion: the proposed diagnostic rules can be considered screening markers for prognosis of a severe form of CMVI in newborns.

scholarly journals Prognosis of severe cytomegalovirus infection in newborns

2021 ◽  
Vol 11 (4) ◽  
pp. 745-751
Author(s):  
L. V. Kravchenko
Keyword(s):  
B Lymphocytes ◽  
Cytomegalovirus Infection ◽  
Severe Form ◽  
T And B Lymphocytes ◽  
T Helper ◽  
Input Stream ◽  
Intercellular Interaction ◽  
Activation Markers ◽  
Systems Of Inequalities ◽  
Consistent Application

Objective is to study the features of impaired activation of T and B lymphocytes in order to predicting severe cytomegalovirus infection in newborns. Materials and methods. 133 newborns with cytomegalovirus infection were examined. Immediately after diagnosing cytomegalovirus infection, all patients observed were immunologically ex amined, including assessing count of peripheral blood T and B lymphocytes, as well as their intercellular interaction by using flow cytometry immunostaining for CD3, CD3+CD28–, CD3+CD28+, CD3–CD28+, CD4, CD8, CD20, CD20+CD40+, CD28, CD40. The test was performed by using a Beckman Coulter Epics XL laser flow cytofluorometer. Depending on the condition severity, all children were divided into two groups: 1 — cytomegalovirus infection, severe form — 60 subjects (45.1%); 2 — cytomegalovirus infection, moderate form — 73 subjects (54.9%). Results of the entire set of studied indicators for cellular and humoral arms of immune system revealed statistically significant differences for the prognosis of severe cytomegalovirus infection: CD3+CD28–, CD20, CD20+CD40+, CD4. T lymphocytes with CD3+CD28+ activation markers, through which costimulating signals necessary for the activation of T helper cells are exerted cell-intrinsic features, serving as an important factor ensuring immune response. Using the “classification trees” method, we developed a differentiated approach to forecast severe cytomegalovirus infection in newborns. Systems of inequalities were obtained, four of which classify a subgroup of newborns with severe cytomegalovirus infection. The consistent application of the obtained inequalities makes it possible to isolate from the input stream of sick patients with a prognosis of the development of severe cytomegalovirus infection. The proposed diagnostic rules can be considered as screening markers for predicting a severe cytomegalovirus infection in newborns, which makes possible the timely onset of specific therapy.

scholarly journals PARAMETERS OF ANTIVIRAL IMMUNITY IN NEWBORNS WITH CYTOMEGALOVIRUS INFECTION IN CASES OF LATE DETECTION OF CYTOMEGALOVIRUS DNA

2018 ◽  
Vol 17 (3) ◽  
pp. 34-37
Author(s):  
L. V. Kravchenko
Keyword(s):  
Monoclonal Antibodies ◽  
Positive Result ◽  
Cytomegalovirus Infection ◽  
Immune Status ◽  
Clinical Symptoms ◽  
Immunocompetent Cells ◽  
Dna Diagnostics ◽  
Membrane Markers ◽  
Late Detection ◽  
Objective Study

Objective: study of immune status indices in newborns  in cases of late detection of cytomegalovirus (CMV) DNA in blood and urine.Methods: 147 newborns  with non-specific clinical symptoms were studied. Тyping of lymphocytes relating to different clusters CD3+, CD69+, CD71+, CD95+ using monoclonal antibodies produced by IMMUNOTECH (France) have been performed. Expression of membrane markers of immunocompetent  cells was measured on a laser flow cytofluorometer Beckman COULTER Epics XL II.Results: In 123 newborns CMVI has been confirmed by the positive result of PCR, while in 24 newborns the negative result was obtained. In 24 three-month old babies, who had a negative  result following DNA diagnostics in the first month  of their life, cytomegalovirus in blood and urine and increase of anti-CMV IgG have been found, which allowed to diagnose CMVI.The following formula reflecting the dependence of CMVI on CD69+ and CD95+ content in newborns having non-specific clinical symptoms in cases of late detection of CMV DNA has been offered.

scholarly journals Systemic Inflammation Suppresses Lymphoid Tissue Remodeling and B Cell Immunity during Concomitant Local Infection

Cell Reports ◽  
2020 ◽  
Vol 33 (13) ◽  
pp. 108567
Author(s):  
Yannick O. Alexandre ◽  
Sapna Devi ◽  
Simone L. Park ◽  
Laura K. Mackay ◽  
William R. Heath ◽  
...  
Keyword(s):  
B Cell ◽  
Systemic Inflammation ◽  
Lymphoid Tissue ◽  
Tissue Remodeling ◽  
Local Infection ◽  
Cell Immunity ◽  
B Cell Immunity

scholarly journals Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Adam K. Wheatley ◽  
Jennifer A. Juno ◽  
Jing J. Wang ◽  
Kevin J. Selva ◽  
Arnold Reynaldi ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Vaccine Development ◽  
Natural Infection ◽  
Population Level ◽  
Cell Dynamics ◽  
Follicular Helper ◽  
Cell Immunity ◽  
Specific Igg ◽  
Over Time

AbstractThe durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B cell and T cell dynamics over time in a cohort of patients who have recovered from mild-moderate COVID-19. Binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection. A similar decline in Spike-specific CD4+ and circulating T follicular helper frequencies occurs. By contrast, S-specific IgG+ memory B cells consistently accumulate over time, eventually comprising a substantial fraction of circulating the memory B cell pool. Modelling of the concomitant immune kinetics predicts maintenance of serological neutralising activity above a titre of 1:40 in 50% of convalescent participants to 74 days, although there is probably additive protection from B cell and T cell immunity. This study indicates that SARS-CoV-2 immunity after infection might be transiently protective at a population level. Therefore, SARS-CoV-2 vaccines might require greater immunogenicity and durability than natural infection to drive long-term protection.

scholarly journals Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003

2020 ◽  
Vol 1 (9) ◽  
pp. 100155
Author(s):  
Huy A. Tu ◽  
Usha K. Nivarthi ◽  
Nancy R. Graham ◽  
Philip Eisenhauer ◽  
Matthew J. Delacruz ◽  
...  
Keyword(s):  
B Cell ◽  
Dengue Vaccine ◽  
Cell Immunity ◽  
Stimulation Of ◽  
B Cell Immunity

scholarly journals Antibody-based therapy of leukaemia

2009 ◽  
Vol 11 ◽  
Author(s):  
John C. Morris ◽  
Thomas A. Waldmann
Keyword(s):  
Monoclonal Antibodies ◽  
T Cell ◽  
B Cell ◽  
Gemtuzumab Ozogamicin ◽  
Cell Leukaemia ◽  
Target Cells ◽  
Immune Effector ◽  
Effector Cells ◽  
Prolymphocytic Leukaemia ◽  
Immune Effector Cells

Over the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma. Currently, only two monoclonal antibodies – the anti-CD33 immunotoxin gemtuzumab ozogamicin and the CD52-directed antibody alemtuzumab – are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively. Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and Sézary syndrome, and adult T cell leukaemia and lymphoma. In addition, rituximab has demonstrated activity against B cell chronic lymphocytic and hairy cell leukaemia. Monoclonal antibodies targeting CD4, CD19, CD20, CD22, CD23, CD25, CD45, CD66 and CD122 are now being studied in the clinic for the treatment of leukaemia. Here, we discuss how these new antibodies have been engineered to reduce immunogenicity and improve antibody targeting and binding. Improved interactions with Fc receptors on immune effector cells can enhance destruction of target cells through antibody-dependent cellular cytotoxicity and complement-mediated cell lysis. The antibodies can also be armed with cellular toxins or radionuclides to enhance the destruction of leukaemia cells.

Monoclonal antibodies that block adhesion of B cell progenitors to bone marrow stromain vitro prevent B cell differentiationin vivo

1991 ◽  
Vol 21 (9) ◽  
pp. 2043-2049 ◽  
Author(s):  
Beat A. Imhof ◽  
Claude Schlienger ◽  
Klaus Handloser ◽  
Barbara Hesse ◽  
Michaela Slanicka ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Monoclonal Antibodies ◽  
B Cell
Sign in / Sign up

Export Citation Format

Share Document